A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood
暂无分享,去创建一个
Rakesh K Jain | R. Jain | D. Scadden | D. Duda | K. Cohen | Dan G Duda | David T Scadden | Kenneth S Cohen | D. Duda
[1] A. Blann,et al. Detection of circulating endothelial cells: CD146-based magnetic separation enrichment or flow cytometric assay? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Tracy T Batchelor,et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.
[3] Robert S. Kerbel,et al. The multifaceted circulating endothelial cell in cancer: towards marker and target identification , 2006, Nature Reviews Cancer.
[4] D. Ross,et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] C. Hudis,et al. Change in circulating endothelial cells (CEC) predicts progression free survival (PFS) in patients (pts) with hormone receptor positive metastatic breast cancer (MBC) receiving letrozole (L) and bevacizumab (B). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Jain,et al. Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Jeffrey W. Clark,et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.
[8] Ricky T. Tong,et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Ricky T. Tong,et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.
[10] C. Heeschen,et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells , 2003, Nature Medicine.
[11] Koichi Hattori,et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? , 2002, Nature Reviews Cancer.
[12] A. Goldhirsch,et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. , 2001, Blood.
[13] G. Pruneri,et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. , 2001, Cancer research.